Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Syngene International Ltd. ( (IN:SYNGENE) ) is now available.
Syngene International Ltd. has confirmed its expansion of biologics capabilities by adding a new ADC bioconjugation facility. This development aims to offer comprehensive services for ADCs, from discovery to GMP manufacturing, enhancing the company’s operational efficiency and market competitiveness in the biopharmaceutical sector.
More about Syngene International Ltd.
Syngene International Ltd. operates in the biopharmaceutical industry, providing integrated research, development, and manufacturing services. The company focuses on biologics, small molecules, and antibody-drug conjugates (ADCs), catering to global pharmaceutical and biotechnology companies.
Average Trading Volume: 40,265
Technical Sentiment Signal: Hold
Current Market Cap: 258.6B INR
See more insights into SYNGENE stock on TipRanks’ Stock Analysis page.